Europe Facial Injectable Market Size & Outlook, 2026-2033
Global Market
Related Markets
Europe facial injectable market highlights
- The Europe facial injectable market generated a revenue of USD 2,895.8 million in 2025.
- The market is expected to grow at a CAGR of 8% from 2026 to 2033.
- In terms of segment, botulinum toxin (botox) was the largest revenue generating product in 2025.
- PLLA is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, France is expected to register the highest CAGR from 2026 to 2033.
Europe data book summary
| Market revenue in 2025 | USD 2,895.8 million |
| Market revenue in 2033 | USD 5,342.1 million |
| Growth rate | 8% (CAGR from 2026 to 2033) |
| Largest segment | Botulinum toxin (botox) |
| Fastest growing segment | PLLA |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Collagen and PMMA Microspheres, Hyaluronic Acid, Calcium Hydroxylapatite (CaHA), PLLA, PCL, PN/PDRN, Botulinum Toxin (Botox) |
| Key market players worldwide | AbbVie Inc, Medytox, Merz Pharma, Revance Therapeutics Inc, Galderma, Sinclair Pharma plc |
Other key industry trends
- In terms of revenue, Europe region accounted for 24.5% of the global facial injectable market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 7,126.5 million by 2033.
The Facial Injectable Market in Europe is witnessing strong growth, driven by rising aesthetic consciousness, increasing disposable income, and advancements in non-invasive cosmetic procedures. A growing number of consumers are opting for minimally invasive treatments to enhance facial features and combat signs of aging without the downtime associated with surgery.
Additionally, technological innovations in injectables, including longer-lasting formulations and improved safety profiles, are fueling market expansion. Regulatory approvals and product launches, such as Merz Aesthetics’ introduction of Ultherapy PRIME in early 2025, reflect Europe’s role as a hub for cutting-edge aesthetic treatments.
With an aging population seeking anti-aging solutions and younger demographics increasingly embracing preventive aesthetics, the demand for facial injectables continues to surge across Europe, positioning the region as a key player in the market.
No credit card required*
Publish Date: May 06, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Facial Injectable Market Scope
Facial Injectable Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Revance Therapeutics Inc | View profile | 597 | 1222 Demonbreun Street, Suite 2000, Nashville, TN, United States, 37203 | www.revance.com |
| Merz Pharma | View profile | 5001-10000 | Deutsch, Sachsen, Germany, Europe | www.merz.com |
| Sinclair Pharma plc | View profile | 501-1000 | London, England, United Kingdom, Europe | www.sinclairpharma.com/ |
| Medytox | View profile | 501-1000 | Seoul, Seoul-t'ukpyolsi, South Korea, Asia | www.medytox.com/page/company_en?site_id=en |
| Ipsen SA | View profile | 5,325 | 65 Quai Georges Gorse, Billancourt Cedex, Boulogne, France, 92100 | www.ipsen.com |
| Galderma | View profile | 10001+ | Lausanne, Vaud, Switzerland, Europe | www.galderma.com |
Europe Facial Injectable Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Facial Injectable Market Outlook will help companies and investors design strategic landscapes.
Botulinum Toxin (Botox) was the largest segment with a revenue share of 50.34% in 2025.
Horizon Databook has segmented the Europe facial injectable market based on collagen and pmma microspheres, hyaluronic acid, calcium hydroxylapatite (caha), plla, pcl, pn/pdrn, botulinum toxin (botox) covering the revenue growth of each sub-segment from 2021 to 2033.
The Facial Injectable Market in Europe is witnessing strong growth, driven by rising aesthetic consciousness, increasing disposable income, and advancements in non-invasive cosmetic procedures. A growing number of consumers are opting for minimally invasive treatments to enhance facial features and combat signs of aging without the downtime associated with surgery.
Additionally, technological innovations in injectables, including longer-lasting formulations and improved safety profiles, are fueling market expansion. Regulatory approvals and product launches, such as Merz Aesthetics’ introduction of Ultherapy PRIME in early 2025, reflect Europe’s role as a hub for cutting-edge aesthetic treatments.
With an aging population seeking anti-aging solutions and younger demographics increasingly embracing preventive aesthetics, the demand for facial injectables continues to surge across Europe, positioning the region as a key player in the market.
- Europe Facial Injectable Market Product Outlook (Revenue, USD Million , 2021-2033)
- Collagen and PMMA Microspheres
- Hyaluronic Acid
- Calcium Hydroxylapatite (CaHA)
- PLLA
- PCL
- PN/PDRN
- Botulinum Toxin (Botox)
- Exosome
- Europe Facial Injectable Market Applications Outlook (Revenue, USD Million , 2021-2033)
- Wrinkle Correction
- Lip Augmentation
- Facial Contouring
- Scar Treatment
- Volume Loss Restoration
- Others
- Europe Facial Injectable Market End Use Outlook (Revenue, USD Million , 2021-2033)
- MedSpas
- Aesthetic Surgery Centers
- Hospitals
- Others
Reasons to subscribe to Facial Injectable Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Facial Injectable Market Outlook databook
- Our clientele includes a mix of Facial Injectable Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe Facial Injectable Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Europe Facial Injectable Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Europe Facial Injectable Market, 2021-2033 (US$M)
Europe facial injectable market statistics, by product, 2021-2033 (US$M)
